An unusual case of respiratory failure in a patient with Randu–Osler–Weber disease. Case report
- Authors: Podzolkov V.I.1, Pokrovskaya A.E.1, Ivanova V.S.1, Krylova K.E.1, Luchkina P.V.1, Murzakhanova F.E.1, Gerasimova D.D.1, Medvedev I.D.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 26, No 12 (2024): Коморбидность в клинике внутренних болезней
- Pages: 886-890
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/289179
- DOI: https://doi.org/10.26442/20751753.2024.12.203097
- ID: 289179
Cite item
Full Text
Abstract
Clinical observation is of interest due to the shift in the vector of the main complaints of the classic manifestation of Randu–Osler–Weber disease in the form of epistaxis and anemia syndrome towards the syndrome of severe respiratory failure, the cause of which is the presence of arteriovenous malformations in the lungs. The importance of an interdisciplinary approach to the diagnosis and treatment of patients with Randu–Osler–Weber disease is discussed.
Full Text
##article.viewOnOriginalSite##About the authors
Valery I. Podzolkov
Sechenov First Moscow State Medical University (Sechenov University)
Email: pokrovskaya_a_e@staff.sechenov.ru
ORCID iD: 0000-0002-0758-5609
D. Sci. (Med.), Prof.
Russian Federation, MoscowAnna E. Pokrovskaya
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: pokrovskaya_a_e@staff.sechenov.ru
ORCID iD: 0000-0002-8875-9032
Cand. Sci. (Med.)
Russian Federation, MoscowVictoria S. Ivanova
Sechenov First Moscow State Medical University (Sechenov University)
Email: pokrovskaya_a_e@staff.sechenov.ru
ORCID iD: 0009-0005-3548-357X
Clinical Resident
Russian Federation, MoscowKseniya E. Krylova
Sechenov First Moscow State Medical University (Sechenov University)
Email: pokrovskaya_a_e@staff.sechenov.ru
ORCID iD: 0009-0009-2485-9008
Clinical Resident
Russian Federation, MoscowPolina V. Luchkina
Sechenov First Moscow State Medical University (Sechenov University)
Email: pokrovskaya_a_e@staff.sechenov.ru
ORCID iD: 0009-0000-8260-2491
Student
Russian Federation, MoscowFatima E. Murzakhanova
Sechenov First Moscow State Medical University (Sechenov University)
Email: pokrovskaya_a_e@staff.sechenov.ru
ORCID iD: 0009-0004-2388-3384
Student
Russian Federation, MoscowDarya D. Gerasimova
Sechenov First Moscow State Medical University (Sechenov University)
Email: pokrovskaya_a_e@staff.sechenov.ru
ORCID iD: 0009-0004-7015-0829
Student
Russian Federation, MoscowIvan D. Medvedev
Sechenov First Moscow State Medical University (Sechenov University)
Email: pokrovskaya_a_e@staff.sechenov.ru
ORCID iD: 0000-0003-4210-2841
Cand. Sci. (Med.)
Russian Federation, MoscowReferences
- Albiñana V, Cuesta AM, Rojas-P I, et al. Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding. J Clin Med. 2020;9(6):1766. doi: 10.3390/jcm9061766
- Shovlin CL. Pulmonary arteriovenous malformations. Am J Respir Crit Care Med. 2014;190(11):1217-28. doi: 10.1164/rccm.201407-1254CI
- Rendu M. Epistaxis repetes chez unsujet porteur de petits angiomies cutaneset muqueux. Bull Mem Soc Med Hop Paris. 1886;13:731-3.
- Osler W. On a family form of recurring epistaxis. Associated with multiple telangiectases of the skin and mucous membranes. Johns Hopkins Med J. 1901;12:333-7.
- Таганов А.В., Тамразова О.Б., Молочков А.В., и др. Современные аспекты болезни Рандю–Ослера–Вебера. Педиатрия им. Г.Н. Сперанского. 2019;98(6):127-33 [Taganov AV, Tamrazova OB, Molochkov AV, et al. Modern aspects of Rendu–Osler–Weber disease. Pediatria Journal named after G.N. Speransky. 2019;98(6):127-33 (in Russian)].
- Ruiz-Llorente L, Gallardo-Vara E, Rossi E, et al. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia. Expert Opin Ther Targets. 2017;21(10):933-47. doi: 10.1080/14728222.2017.1365839
- Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010;24(6):203-19. doi: 10.1016/j.blre.2010.07.001
- Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet. 2006;43(2):97-110. doi: 10.1136/jmg.2005.030833
- Мизерницкий Ю.Л., Шатоха П.А., Соколова Л.В. Болезнь Рандю-Ослера-Вебера (наследственная геморрагическая телеангиэктазия) с поражением органов дыхания. Пульмонология. 2023;33(2):216-24 [Mizernitskiy YuL, Shatokha PA, Sokolova LV. Randu–Osler–Weber disease (or hereditary hemorrhagic teleangectasia) with respiratory involvement. Pulmonologiya. 2023;33(2):216-24 (in Russian)]. doi: 10.18093/0869-0189-2023-33-2-216-224
- Sadick H, Hage J, Goessler U, et al. Does the genotype of HHT patients with mutations of the ENG and ACVRL1 gene correlate to different expression levels of the angiogenic factor VEGF? Int J Mol Med. 2008;22(5):575-80.
- Braverman IM, Keh A, Jacobson BS. Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol. 1990;95(4):422-7. doi: 10.1111/1523-1747.ep12555569
- Gallione CJ, Repetto GM, Legius E, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004;363(9412):852-9. doi: 10.1016/S0140-6736(04)15732-2.
- van Gent MW, Post MC, Snijder RJ, et al. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest. 2010;138(4):833-9. doi: 10.1378/chest.09-1849
- Di Guardo F, Lo Presti V, Costanzo G, et al. Pulmonary Arteriovenous Malformations (PAVMs) and Pregnancy: A Rare Case of Hemothorax and Review of the Literature. Case Rep Obstet Gynecol. 2019;2019:8165791. doi: 10.1155/2019/8165791
- Welle CL, Welch BT, Brinjikji W, et al. Abdominal manifestations of hereditary hemorrhagic telangiectasia: a series of 333 patients over 15 years. Abdom Radiol (NY). 2019;44(7):2384-31. doi: 10.1007/s00261-019-01976-7
- Lebrin F, Srun S, Raymond K, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. 2010;16(4):420-8. doi: 10.1038/nm.2131
- Rohrmeier C, Sachs HG, Kuehnel TS. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol. 2012;269(2):531-6. doi: 10.1007/s00405-011-1721-9
- Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009;361(9):931. doi: 10.1056/NEJMc091271
- Riss D, Burian M, Wolf A, et al. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Head Neck. 2015;37(6):783-7. doi: 10.1002/hed.23655
Supplementary files
